


TALZENNA[®] +
talazoparib 0.5 mg capsules


Xtandi[®]
(enzalutamide)
40 mg tablets | 80 mg tablets

EXPLORE TALZENNA + XTANDI

USE

TALZENNA is a prescription medicine used in combination with a medicine called enzalutamide, to treat adults with prostate cancer

- with certain abnormal inherited or acquired genes called homologous recombination repair (HRR genes) **and**
- which no longer responds to a hormone therapy or surgical treatment to lower testosterone and has spread to other parts of the body (metastatic).

Your healthcare provider will perform a test to make sure that TALZENNA is right for you.

It is not known if TALZENNA is safe and effective in children.



IMPORTANT SAFETY INFORMATION

TALZENNA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).

Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with TALZENNA.

MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with TALZENNA.

Please see additional Important Safety Information throughout. Click for the full TALZENNA [Patient Information](#) or visit [TALZENNAXTANDI.com](https://www.talzennaxtandi.com). Please talk to your doctor or see XTANDI Patient Information for Important Safety Information about XTANDI.

STARTING TALZENNA + XTANDI

TALZENNA is a prescription medicine used in combination with a medicine called enzalutamide to treat adults with **metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations** (HRR gene-mutated mCRPC).

HRR gene-mutated mCRPC is prostate cancer with certain abnormal inherited or acquired genes called homologous recombination repair (HRR) that has spread to other parts of the body (metastatic) and no longer responds to hormone therapy or surgical treatment to lower testosterone (castration-resistant).

HRR GENE MUTATIONS EXPLAINED

HRR is a process in which a group of genes work together to repair damage to your DNA. If you have mutations in HRR genes, not all DNA repair proteins may work properly. This may increase your chances of developing certain types of cancers, including prostate cancer.

Once-Daily Oral Treatment

TALZENNA is a pill—not chemotherapy or an injection. It's taken:



Once a day



With or without food

There Are 2 Types of HRR Gene Mutations:

Inherited

Passed on from parent to child

Acquired

Can occur randomly and throughout your lifetime

~ 1 in 4 Men With mCRPC Have an HRR Gene Mutation*

*This is an estimate because the studies and data used to determine the occurrence of HRR gene mutations in men with advanced prostate cancer varied in their design and patient characteristics, such as different previous or current drug treatment, coexisting conditions, or disease levels.



Please see additional Important Safety Information throughout. Click for the full [TALZENNA Patient Information](#) or visit [TALZENNAXTANDI.com](#). Please talk to your doctor or see XTANDI Patient Information for Important Safety Information about XTANDI.



WHY HRR STATUS MATTERS

For starters, knowing your HRR status can inform your treatment options, including whether you might be eligible for TALZENNA + XTANDI. But it can also:

- Help you and your doctor decide how to manage your prostate cancer
- Help you find out if your family is at an increased risk of developing certain types of cancers since these mutations may be inherited



HOW HRR GENE MUTATIONS ARE IDENTIFIED

A doctor can perform a genetic/germline (inherited) and/or somatic (acquired) test to determine if there are HRR gene mutations. Genetic testing can be done using a tissue or blood sample.

ASK YOUR DOCTOR ABOUT YOUR HRR MUTATION STATUS

They may have already tested for HRR mutations and can review the results with you. If this testing hasn't been done yet, your doctor can help coordinate the appropriate genetic test.

HRR = homologous recombination repair.

IMPORTANT SAFETY INFORMATION

TALZENNA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).
(Continued)

Symptoms of low blood cell counts are common during treatment with TALZENNA, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with TALZENNA:

- weakness
- frequent infections
- feeling very tired
- weight loss
- blood in urine or stool
- bruising or bleeding more easily
- fever
- shortness of breath

Your healthcare provider will do blood tests to check your blood cell counts:

- every month during treatment with TALZENNA
- weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with TALZENNA until your blood cell counts improve.





HOW THIS TREATMENT MAY HELP

THE STUDY

TALZENNA + XTANDI was studied in a clinical trial in adults with HRR gene-mutated mCRPC. The main goal of the study was to look at progression-free survival. Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason.

All men either had surgery to lower testosterone or continued to take hormone therapy in the study.

 **200**
patients were given
TALZENNA + XTANDI

 **199**
patients were given
placebo + **XTANDI**

IMPORTANT SAFETY INFORMATION

Before taking TALZENNA, tell your healthcare provider about all of your medical conditions, including if you:

- have kidney problems
- are pregnant or plan to become pregnant. TALZENNA can harm your unborn baby, and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with TALZENNA. Tell your healthcare provider right away if you are pregnant or become pregnant during treatment with TALZENNA.
 - Males with female partners who are pregnant or are able to become pregnant should use effective birth control during treatment with TALZENNA and for at least 4 months after receiving the last dose of TALZENNA.
- are breastfeeding or plan to breastfeed. It is not known if TALZENNA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. Taking TALZENNA and certain other medicines can affect how TALZENNA works and may cause side effects.


Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

THE RESULTS

REDUCED RISK OF PROGRESSION


The risk of cancer progression was **reduced by 55% with TALZENNA + XTANDI** vs those taking placebo + XTANDI.

Cancer progression was seen in 66 of the 200 (33.0%) men taking TALZENNA + XTANDI vs 104 of the 199 (52.3%) men taking placebo + XTANDI. Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason.



MEDIAN TIME UNTIL CANCER PROGRESSION

During this study, cancer progression was measured by the median. The median is not the average but the middle of a set of numbers. The median time until cancer progression is how long it takes until cancer in half of the patients in the study starts growing or spreading again or if they die for any reason.



The median length of time until the cancer grew or spread was not reached for **TALZENNA + XTANDI**.* In this clinical trial, patients taking **TALZENNA + XTANDI** had a **97.5% chance that the median time until cancer progression was at least 21.9 months.**

The median length of time until the cancer grew or spread was **13.8 months** for a placebo + **XTANDI**.

More time is needed to find out if patients taking TALZENNA + XTANDI live longer than patients taking placebo + XTANDI.

*What does “median not reached for TALZENNA + XTANDI” mean? “Median not reached” means that more than half of patients were alive without their cancer progressing at the time of analysis.



HOW TREATMENT WORKS

TALZENNA + XTANDI treats HRR gene-mutated mCRPC in 2 different ways.

HOW TALZENNA WORKS

The DNA in the nucleus of your cells tells your body how to form and function. DNA is arranged in groupings called genes, which make proteins that drive this process. Importantly, DNA regulates the ability of cells to duplicate to keep the process going. But DNA can become damaged.



When there's damaged DNA, called breaks in the DNA strands, proteins such as PARP,* which exist in your cells, help repair the breaks to keep the cells functioning. This occurs for both normal and cancerous cells.



*PARP = poly (ADP-ribose) polymerase.

HRR provides another mechanism for DNA repair. In cells, there may be damage to HRR genes due to mutations. Mutated HRR genes prevent proteins associated with the pathway from being effective in DNA repair.



TALZENNA is for men whose prostate cancer has an HRR gene mutation. TALZENNA works by inhibiting the repair protein, PARP, from activating the cell's repair pathway. This, in combination with the dysfunction of the mutated HRR gene, makes it harder for cancer cells to survive. TALZENNA can also affect normal cells, which can lead to side effects.



This is how TALZENNA was shown to work in laboratory studies. Clinical significance is unknown.

HOW XTANDI WORKS

XTANDI is an androgen receptor inhibitor.



Androgens are a group of hormones that include testosterone. Androgen receptor inhibitors decrease how often androgens like testosterone connect with an androgen receptor, and thereby may slow the growth of prostate cancer tumors and cells. Let's take a look inside the cell.

When androgen connects with an androgen receptor, it may cause tumor cells to grow.



XTANDI helps decrease how often androgen can connect with an androgen receptor. As a result, XTANDI can slow cancer cell growth and the cancer cells may die.

This is how XTANDI was shown to work in laboratory studies. Clinical significance is unknown.

Please talk to your doctor or see XTANDI Patient Information for important safety information about XTANDI.

IMPORTANT SAFETY INFORMATION

How to take TALZENNA

- Take TALZENNA exactly as your healthcare provider tells you.
- Do not change your dose or stop taking TALZENNA without first talking with your healthcare provider.
- You should start or continue a gonadotropin-releasing hormone (GnRH) analog therapy during your treatment with TALZENNA and enzalutamide unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).
- If you miss a dose of TALZENNA or vomit, take your next dose at your regular time. Do not take an extra dose to make up for a missed dose.
- If you take too much TALZENNA, call your healthcare provider or go to the nearest hospital emergency room right away.



IMPORTANT SAFETY INFORMATION

TALZENNA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).

Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with TALZENNA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with TALZENNA.

Symptoms of low blood cell counts are common during treatment with TALZENNA, but can be a sign of serious problems, including MDS or AML. Tell your healthcare provider if you have any of the following symptoms during treatment with TALZENNA:

- weakness
- weight loss
- fever
- frequent infections
- blood in urine or stool
- shortness of breath
- feeling very tired
- bruising or bleeding more easily

Your healthcare provider will do blood tests to check your blood cell counts:

- every month during treatment with TALZENNA
- weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with TALZENNA until your blood cell counts improve.

Before taking TALZENNA, tell your healthcare provider about all of your medical conditions, including if you:

- have kidney problems
- are pregnant or plan to become pregnant. TALZENNA can harm your unborn baby, and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with TALZENNA. Tell your healthcare provider right away if you are pregnant or become pregnant during treatment with TALZENNA.
 - Males with female partners who are pregnant or are able to become pregnant should use effective birth control during treatment with TALZENNA and for at least 4 months after receiving the last dose of TALZENNA.
- are breastfeeding or plan to breastfeed. It is not known if TALZENNA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. Taking TALZENNA and certain other medicines can affect how TALZENNA works and may cause side effects.

Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

How to take TALZENNA

- Take TALZENNA exactly as your healthcare provider tells you.
- Do not change your dose or stop taking TALZENNA without first talking with your healthcare provider.
- You should start or continue a gonadotropin-releasing hormone (GnRH) analog therapy during your treatment with TALZENNA and enzalutamide unless you have had a surgery to lower the amount of testosterone in your body (surgical castration).
- If you miss a dose of TALZENNA or vomit, take your next dose at your regular time. Do not take an extra dose to make up for a missed dose.
- If you take too much TALZENNA, call your healthcare provider or go to the nearest hospital emergency room right away.

The most common side effects of TALZENNA when taken in combination with enzalutamide include:

- low red blood cell counts
- low white blood cell counts
- tiredness or weakness
- low platelet counts
- low calcium in the blood
- nausea
- decreased appetite
- low sodium in the blood
- low phosphate in the blood
- bone injuries
- low magnesium in the blood
- dizziness
- increased bilirubin in the blood
- low potassium in the blood
- changes in your sense of taste

TALZENNA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of TALZENNA. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATION

TALZENNA is a prescription medicine used in combination with a medicine called enzalutamide, to treat adults with prostate cancer

- with certain abnormal inherited or acquired genes called homologous recombination repair (HRR genes) **and**
- which no longer responds to a hormone therapy or surgical treatment to lower testosterone and has spread to other parts of the body (metastatic).

Your healthcare provider will perform a test to make sure that TALZENNA is right for you.

It is not known if TALZENNA is safe and effective in children.

LEARN MORE ABOUT CERTAIN SIDE EFFECTS

Before you start taking TALZENNA + XTANDI, it's important to know what to expect during treatment. Stay informed and work with your doctor to identify and manage any side effects that you may experience.

MONITORING BLOOD CELL COUNTS

Some side effects like low red/white blood cell counts, low sodium/calcium in the blood, and low platelet counts can only be seen through blood tests, which your doctor will do:

- every month during treatment with TALZENNA
- weekly if you have low blood cell counts that last a long time. Your doctor may stop treatment with TALZENNA until your blood cell counts improve.

COMMON SIDE EFFECTS

The most common side effects of **TALZENNA** when taken in combination with **XTANDI** include:

- low red blood cell counts
- low white blood cell counts
- tiredness or weakness
- low platelet counts
- low calcium in the blood
- nausea
- decreased appetite
- low sodium in the blood
- low phosphate in the blood
- bone injuries
- low magnesium in the blood
- dizziness
- increased bilirubin in the blood
- low potassium in the blood
- changes in your sense of taste

Your doctor may modify your treatment dose or have other suggestions that could be helpful.



TIPS THAT MAY HELP WITH CERTAIN SIDE EFFECTS

Here are some lifestyle changes that could help you deal with common side effects. These tips come from organizations that focus on supporting patients and have not been studied with TALZENNA. Check with your doctor to see which may be right for you.

LOW RED BLOOD CELL COUNTS

Treatment may cause a decrease in the number of red blood cells, known as anemia. Anemia may make you feel very tired, short of breath, and/or lightheaded.



Tip: Ask your doctor if any dietary changes or supplements could be helpful.

LOW WHITE BLOOD CELL COUNTS

During treatment, you may experience a decrease in white blood cell numbers, which could put you at an increased risk of infection.



Tip: Remember to wash your hands often and minimize your exposure to people who may be sick.

TIREDNESS OR WEAKNESS

While on treatment, you may experience fatigue. Anemia could also contribute to the feeling of tiredness or weakness.



Tip: Talk with your doctor about the amount of rest and kinds of activities that are right for you.

LOW PLATELET COUNTS

Platelets are cells that help your blood to clot and stop bleeding. Treatment may cause the number of blood-platelet cells to decrease, which could increase your risk of bruising and bleeding.



Tip: Discuss all over-the-counter medicines you're taking with your doctor, especially those that may increase your risk of bleeding.

LOW CALCIUM IN THE BLOOD

Treatment may cause low levels of calcium in the blood. This may lead to muscle cramps, especially in your back and legs.



Tip: Talk to your doctor about how you might be able to help maintain your calcium levels.

NAUSEA

During treatment, you may experience nausea or an upset stomach.



Tip: It may be helpful to eat several small meals throughout the day instead of 3 large ones. It may help to slowly sip liquids throughout the day.

DECREASED APPETITE

Treatment may lower your appetite, which could lead to not eating enough nutrients. Nausea may also contribute to loss of appetite.



Tip: Speak with your care team about foods that might be most nourishing for you.

LOW SODIUM IN THE BLOOD

Treatment may cause sodium levels in the blood to be lower than normal. This may cause nausea and vomiting, low energy, and/or headaches.



Tip: There may be dietary suggestions your care team can share that could help increase your sodium levels.

These are not all of the possible side effects of TALZENNA. Call your doctor for medical advice about side effects.


You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

FINANCIAL ASSISTANCE RESOURCES

MEDICARE/GOVERNMENT INSURED

For eligible patients with Medicare/Medicare Part D, Medicaid, or other government insurance plans who express a financial need:

- We can assist patients with searching for financial support from alternate funding resources, which may include financial assistance through Extra Help, a Medicare Part D Low-Income Subsidy (LIS) program
- If support from alternate funding resources or Medicare Extra Help is not available, Pfizer Oncology Together will see if patients are eligible for the Pfizer Patient Assistance Program,* which can provide prescribed Pfizer Oncology medicines for free



*The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. Free medicines from Pfizer are provided through the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation™ is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

COMMERCIALLY INSURED

For patients with eligible commercial, private, employer, and state marketplace health insurance plans:

CO-PAY ASSISTANCE: Eligible, commercially insured patients may pay as little as \$0 per month for their Pfizer Oncology treatment. [Limits, terms, and conditions apply.](#)† Patients may receive up to \$10,000 per product in savings annually.



†Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico.



UNINSURED

For eligible patients without any form of healthcare coverage:

- We can check patient eligibility for Medicaid and help them understand how to apply
- Patients who do not qualify for Medicaid may receive free medicine through the Pfizer Patient Assistance Program.‡ Patients must be eligible and reapply as needed

*The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. Free medicines from Pfizer are provided through the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation™ is a separate legal entity from Pfizer Inc. with distinct legal restrictions.



FIND SUPPORT ANYTIME, ANYWHERE



MyTHERAPY[®] APP

Now customized with TALZENNA content to support you on your treatment journey. It's available on the App Store and Google Play and includes:



MEDICATION REMINDERS

Manage your medications in one place and stay on top of your TALZENNA therapy with **personalized reminders**.



EDUCATION

Get informed about your treatment with **articles and content**. Plus, information about side effects.



SUPPORT

Find additional support **services and tools** relevant to you and your care.



PROGRESS TRACKER

Discover ways to **stay on track**—set reminders, log habits, and record progress. You can also download your health report to discuss with your doctor at your next appointment.



Scan the QR code to download MyTHERAPY[®] and register today

For patients prescribed TALZENNA + XTANDI[®] (enzalutamide)



THIS IS LIVING WITH CANCER[™] PROGRAM

Developed by Pfizer Oncology, this program supports cancer patients and their loved ones. It is available to anyone in the U.S., regardless of cancer type or stage of disease, whether or not they are on a Pfizer treatment.



UNDERSTANDING CANCER

Find encouragement, education, and tools to help you navigate your treatment journey.



HEALTH & WELLNESS

Explore articles about healthy living, exercise, and dietary considerations. Plus, find resources on managing depression, anxiety, pain, and more.



PERSONALIZED SUPPORT

Access support and resources that are tailored to your needs, whether you are a patient or caregiver.



LIVINGWITH[®] APP

Stay connected, organized, and informed—all in one place. This free app helps you and your support network better manage daily life with cancer. Available on the App Store and Google Play.



Scan the QR code to visit ThisIsLivingWithCancer.com

Learn more and download the LivingWith[®] app for free. Available in English and Spanish.




TALZENNA[®] +
talazoparib 0.5mg
capsules


Xtandi[®]
(enzalutamide)
40 mg tablets | 80 mg tablets



GET TO KNOW MORE ABOUT
TALZENNA

Visit **TALZENNAXTANDI.com**

Please see Important Safety Information throughout. Click for the full TALZENNA [Patient Information](#) or visit TALZENNAXTANDI.com. Please talk to your doctor or see XTANDI Patient Information for Important Safety Information about XTANDI.

TALZENNA[®] is a registered trademark of Pfizer Inc.
XTANDI[®] is a registered trademark of Astellas Pharma Inc.
© 2025 Pfizer Inc. All rights reserved.
PP-TXT-USA-0486 March 2025

